Seattle-based startup Rodeo Therapeutics is raising more cash for its work on tissue repair and regeneration.
The company has reeled in another $4.3 million, according to a new regulatory filing, adding to an investment round that also included a $3.7 million cash infusion late last year.
Rodeo, which raised a $5.9 million Series A round in 2017, declined to comment on the new funding.
The biotech startup is focused on creating treatments for inflammatory bowel disease as well as a drug that helps cancer patients’ cells grow quickly following stem cell transplants.
Rodeo was started by gastrointestinal cancer expert Dr. Sanford Markowitz, stem cell and drug development specialist Dr. Stanton Gerson, and regenerative medicine expert Dr. Joseph Ready. Thong Le is the company’s CEO; he’s also president and CEO of Seattle-based Accelerator Life Science Partners, one of Rodeo’s investors.
Regenerative medicine holds the promise of creating new tissues to replace damaged ones. Rodeo’s therapies could one day help the 3 million Americans living with an inflammatory bowel disease, such as Crohn’s disease, as well as the 22,000 who receive a bone marrow or umbilical cord blood transplant each year.
Rodeo’s investors include AbbVie, Lilly, Arch Venture Partners and Johnson & Johnson, among others. The new regulatory filing listed the following venture investors:
- Steve Gillis, managing director at Arch Venture Partners
- Asish Xavier, vice president of venture investments at Johnson & Johnson Development Corporation
- Joel Marcus, founder of Alexandria Venture Investments
- Tadataka Yamada, venture partner at Frazier Healthcare
- Margarita Chavez, managing director at AbbVie Ventures
